Madison Vaccines Incorporated Announces Expansion of a Phase 2 Clinical Trial for MVI-816, Its Lead DNA Vaccine for Prostate Cancer

MVI-816 Intended to Delay Metastatic Disease after Primary Therapy, but Before Hormonal Therapy Trial Now Enrolling at University of Wisconsin, with Additional Centers to Follow June 23, 2014 Madison Vaccines Incorporated (MVI), a clinical stage biopharmaceutical company, today announced enrollment has begun in the expansion of a Phase 2 clinical trial of its lead product candidate MVI-816 (pTVG-HP). The expansion …